Kari Johansen has specialty degrees in Pediatrics (2000) and Clinical Virology (2003) from the Karolinska University Hospital and her PhD (1999) from the Karolinska Institute, Sweden on Immune responses related to protection against rotavirus. In Sweden, she has served the Public Health Agency of Sweden during the years 2000-2008 and from 2021 and onwards as a senior consultant with initial responsibility for the WHO MR laboratory that included national seroepidemiological studies of measles, mumps, rubella, varicella antibodies as well as B-cell memory following MMR vaccination. More recently, she has focused on national vaccine policy recommendations for mpox, varicella, zoster, RSV and COVID-19 vaccines and is engaged in vaccination strategy studies for mpox vaccination. At the European level, Dr Johansen served the EU Agency European Centre for Disease Prevention and Control (ECDC) 2008 - 2021 leading EU-wide projects assessing vaccine coverage, influenza vaccine safety (narcolepsy, GBS), influenza vaccine effectiveness using data linkage of European electronic databases and represented the ECDC in EMA Vaccine Working Party. In 2018 she initiated an EU NITAG Collaboration assessing scientific evidence through systematic reviews in support of national policy decision making. Globally, Dr Johansen served as a Member of WHO SAGE on immunizations from 2014 to 2021, where she was elected vice Chair in 2016 and represented SAGE in the Global Advisory Committee on Vaccine Safety. She has published > 60 scientific publications and is co-author of the chapter Immunization in Europe in the last two Editions of Plotkin’s Vaccines (2016, 2023).